Vertiv Holdings (NYSE:VRT) has completed its acquisition of King Environmental Services (KES), expanding its thermal management services across Europe, the Middle East and Africa.
Eikon Therapeutics (NASDAQ:EIKN) presented updated Phase 2 TeLuRide-005 results showing a 63.1% objective response rate with EIK1001 combined with pembrolizumab and chemotherapy in previously untreated patients with stage 4 non-small cell lung cancer.
Amanat Acquisition (NASDAQ:AMAN) and Corxel US signed a definitive business combination agreement intended to create a publicly traded biopharmaceutical company focused on obesity treatments, with approximately $377 million in potential gross proceeds.
EQT Corporation (NYSE:EQT) announced an agreement to acquire Range Resources (NYSE:RRC) in an all-stock transaction expected to create a natural gas producer with a pro forma enterprise value exceeding $50 billion.
BioNTech (NASDAQ:BNTX) and DualityBio announced that trastuzumab pamirtecan met the primary endpoint of the global Phase 3 DYNASTY-Breast02 trial in patients with HR-positive, HER2-low metastatic breast cancer.
HUTCHMED (NASDAQ:HCM) reported Phase III SANOVO results showing that ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in previously untreated EGFR-mutated lung cancer patients.
Borr Drilling (NYSE:BORR) said five personnel remained unaccounted for after its Prospector 5 jack-up drilling rig sank offshore Gabon on October 24, 2026.
Phathom Pharmaceuticals (NASDAQ:PHAT) announced that the U.S. Food and Drug Administration established a public docket seeking comments on regulatory questions involving VOQUEZNA's exclusivity protections through May 3, 2032.
Elbit Systems (NASDAQ:ESLT) announced approximately $200 million in contracts to supply airborne intelligence, surveillance, targeting and training solutions to an undisclosed Asia-Pacific country.
Oil prices fell around 2% on Monday, October 26, 2026, as hopes of easing hostilities between the United States and Iran reduced some geopolitical concerns following last week's rally.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
